IIL to produce drug substance for Covaxin from June Press Trust of India May 29, 2021 Plans to dispatch the first batch to Bharat Biotech by July
Moderna, Samsung Biologics sign agreement for fill-finish manufacturing of COVID-19 vaccine EP News Bureau May 22, 2021 The agreement will further enable global supply of mRNA-1273, Moderna’s COVID-19 vaccine with Samsung Biologics’ fill and finish…
Kejriwal asks PM to share vaccine formula with pharma firms to ramp up manufacturing Press Trust of India May 11, 2021 He said the Centre can also terminate the monopoly on vaccine production through the patent law
PHDCCI urges GOI to enable voluntary licensing and urgently ramp up manufacture of Covaxin,… EP News Bureau May 6, 2021 The Government should try to incentivise directly the foreign companies which own the patents for the other COVID-19 vaccines also…
Sanofi to manufacture Moderna COVID-19 vaccine Press Trust of India Apr 28, 2021 The deal involves up to 200 million doses of Moderna's two-shot vaccine
Pfizer interested in producing vaccine in India if speedy clearance, export freedom assured: Reports Reuters Mar 11, 2021 Pfizer withdrew an application last month seeking EUA for its product in India after the DCGI declined its request to skip a small…
J&J to bring COVID-19 vaccine to India in partnership with Biological E Reuters Feb 10, 2021 Biological E has said it can produce 600 million doses for J&J and more than one billion doses a year of its own vaccine,…
Recipharm, Moderna sign deal for manufacturing, fill-finish of COVID-19 vaccines EP News Bureau Dec 31, 2020 They have reached an agreement to support formulation and fill-finish a part of the Moderna COVID-19 vaccine supply outside of the…
Bharat Biotech to manufacture Covaxin from Odisha EP News Bureau Nov 7, 2020 Dr Ella informs that the best of the technology will be put in the Odisha unit at a total investment of around Rs 300 crores
Novavax expands deal with Serum Institute, aims for two billion COVID-19 vaccine doses Reuters Sep 15, 2020 Serum Institute will also manufacture the antigen component of the vaccine, dubbed NVX‑CoV2373